Intervacc develop novel veterinary vaccines and the pipeline is based on new technology using recombinant proteins rather than attenuated live strains found in conventional vaccines. This results in vaccines with much lower incidence of side effects usually seen with conventional vaccines, something we take pride in as it greatly contributes to an improved animal welfare.

A strong team with extensive knowlegde in Animal Health Care.

The company have its own sales organisation within the Nordic countries and the Baltic states through its subsidiary Nordvacc Läkemedel AB. Nordvacc have a long standing history of supplying this market with animal welfare products for over 30 years.

Our ISO-certified and well-renowned subsidiary the Mybac-Vettech laboratory, offers bacteriological and mycological analyses on the Swedish market.

Intervacc and its subsidiaries have, in addition to a network of consultants, 13 permanently employed coworkers at Hägersten outside Stockholm proper and in Denmark, Latvia, Lithuania, and Finland.

Together we comprise a strong force of skilled and enthusiastic coworkers committed to animal welfare.

ABGSC Investor Day

Intervacc participated in ABGSC Investor Day on September 7, 2020 in Stockholm. CEO Andreas Andersson presented the company and a resume of the first half year. With a strong cash position we now have the opportunity to act long-term and aggressively in the global launch of Strangvac®, our vaccine against the horse disease strangles.

Here you can see the recorded presentation which is about 26 minutes including the following Q&A.